Xenon Pharmaceuticals
XENE
213 hedge funds and large institutions have $2.89B invested in Xenon Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 78 increasing their positions, 71 reducing their positions, and 27 closing their positions.
198% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $3.54M
10% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 71
0.85% more ownership
Funds ownership: 97.43% → 98.28% (+0.85%)
3% less funds holding
Funds holding: 220 → 213 (-7)
9% less capital invested
Capital invested by funds: $3.16B → $2.89B (-$272M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
Top Buyers
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$50.1M |
| 2 |
CC
Commodore Capital
New York
|
+$23.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$15M |
| 4 |
O
OrbiMed
New York
|
+$12.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$11.8M |
Top Sellers
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$28.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$19.6M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$17.7M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
-$13.6M |
XENE Hedge Fund Activity: Q2 2024 in Review
213 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2024, worth a combined $2.89B — down 8.6% from $3.16B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of XENE and 21 opened new positions — a net loss of 6 holders — while 71 trimmed existing stakes and 78 added.
The largest buyer was Braidwell, adding an estimated $50.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $28.2M.
- 213 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2024, down from 220 in Q1 2024.
- Funds reported $2.89B of Xenon Pharmaceuticals stock for Q2 2024, down 8.6% quarter-over-quarter.
- 21 funds opened new Xenon Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of -6 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2024 was Braidwell, an estimated $50.1M added.
- The largest Xenon Pharmaceuticals seller in Q2 2024 was Lord, Abbett & Co, an estimated $28.2M sold.
Based on aggregated 13F filings for Q2 2024.